Forest, Almirall Announce Submission of New Drug Application for Aclidinium Bromide

Forest Laboratories and Almirall, S.A. announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for aclidinium bromide, a long-acting inhaled antimuscarinic agent developed for the treatment of Chronic Obstructive Pulmonary Disease.
MarketWatch